



Phosphagenics: Oxycodone Patch Resumes Clinical Development

5 April 2013, Melbourne: Australian drug delivery technology company, Phosphagenics Limited (ASX: POH, OTCQX: PPGNY), will be returning to the clinic with its oxycodone TPM[®] transdermal patch.

The Company has received ethics approval to conduct a further clinical trial at the Royal Adelaide Hospital's independent CMAX facility. The trial is designed to assess the profile of the new patch and form an integral part of the clinical program for 2013. Results are expected at the beginning of Q3.

Final design specifications of this transdermal patch technology have been completed in collaboration with our European development partner, tesa Labtec GmbH.

Oxycodone is one of the lead candidates in the Company's opioid transdermal delivery portfolio, which includes a range of opioid patch products targeting all levels of chronic pain. It has application for the more traditional systemic delivery as well as significant potential for use in topical application.

This latest trial follows a recent Phase 1 study of the Company's transdermal TPM[®] oxymorphone patch, which demonstrated outstanding results and successfully met the primary endpoints of safety and delivery of oxymorphone into the bloodstream for 72 hours.

Phosphagenics CEO, Dr Esra Ogru, said: "Returning to the clinic with our oxycodone patch technology is an important milestone in progressing our pain patch clinical programs during 2013."

Previously announced market research data has indicated projected demand for a TPM[®]/oxycodone patch is expected to exceed \$1 billion per annum. The current global oxycodone market exceeds \$3 billion per annum.

Ends

Enquiries:

Dr Esra Ogru
Chief Executive Officer
Phosphagenics Limited
+61 3 9565 1119

David Segal
Investor Relations Manager
Phosphagenics Limited
+61 3 9565 1103

Rudi Michelson
Monsoon Communications
+61 3 9620 3333

Phosphagenics Limited

ACN 056 482 403 ABN 32 056 482 403

11 Duerdin Street, Clayton VIC 3168
PO Box 1415, Clayton South MDC VIC 3169 Australia
Tel: +61 (0)3 9565 1119 Fax: +61 (0)3 9565 1151
Web: www.phosphagenics.com Email: info@phosphagenics.com

About Phosphagenics

Phosphagenics Limited is commercialising drug delivery applications based on its novel transdermal (drugs administered via skin) TPM[®] – Targeted Penetration Matrix technology. TPM[®] is a patient friendly and cost effective system used to deliver proven pharmaceutical and nutraceutical products.

The lead product advancing through clinical trials is an oxycodone and oxymorphone matrix system for the relief of chronic pain.

Phosphagenics' shares are listed on the Australian Securities Exchange (POH) and its ADR – Level 1 program in the US is with The Bank of New York Mellon (PPGNY).

www.phosphagenics.com

www.elixia.com.au